Anderson ES et al. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer 2017;5(1):76. Abstract
Ascierto PA et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Proc ESMO 2017;Abstract LBA18.
Ascierto PA et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. Proc ASCO 2017;Abstract 9520.
Basset-Séguin N et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017;86:334-48. Abstract
Brahmer JR et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract
Cecchini M et al. Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. J Immunother Cancer 2015;3:10. Abstract
Chen L et al. Treatment of advanced basal cell carcinoma with sonidegib: Perspective from the 30-month update of the BOLT trial. Future Oncol 2018;14(6):515-25. Abstract
Daud A et al. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol 2017;10(1):3. Abstract
Davies MA et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18(7):863-73. Abstract
Dummer R et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19(5):603-15. Abstract
Dummer R et al. Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. Proc ASCO 2018;Abstract 9574.
Dummer R et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018;19(10):1315-27. Abstract
Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018;378(19):1789-801. Abstract
Eggermont AMM et al. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol 2018;15(9):535-6. Abstract
Escorcia FE et al. Radiotherapy and immune checkpoint blockade for melanoma: A promising combinatorial strategy in need of further investigation. Cancer J 2017;23(1):32-9. Abstract
Gogas H et al. Adverse events of special interest in the phase 3 COLUMBUS study. Proc ASCO 2018;Abstract 9567.
Gopalakrishnan V et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359(6371):97-103. Abstract
Grob JJ et al. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer 2018;91:168-70. Abstract
Hodi FS et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19(11):1480-92. Abstract
Kaufman HL et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018;6(1):7. Abstract
Lewis K et al. BRIM8: A randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence. Proc ESMO 2017;Abstract LBA7_PR.
Long GV et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. Proc ASCO 2018;Abstract 108.
Long GV et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 2018;36(7):667-73. Abstract
Long GV et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017;377(19):1813-23. Abstract
Migden MR et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379(4):341-51. Abstract
Nghiem P et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. Proc ASCO 2018;Abstract 9507.
Rischin CD et al. Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). Proc ASCO 2018;Abstract 9519.
Rodrigues M et al. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat Commun 2018;9(1):1866. Abstract
Tawbi HA et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379(8):722-30. Abstract
Tawbi HA et al. New era in the management of melanoma brain metastases. Am Soc Clin Oncol Educ Book 2018;(38):741-50. Abstract
Warner AB, Postow MA. Combination controversies: Checkpoint inhibition alone or in combination for the treatment of melanoma? Oncology (Williston Park) 2018;32(5):228-34. Abstract
Weber JS et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). Proc ASCO 2018;Abstract 9502.
Weber J et al; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377(19):1824-35. Abstract
Wenwen D et al. TIM-3 as a target for cancer immunotherapy and mechanisms of action. Int J Mol Sci 2017;18(3):645. Abstract
Wolchok JD et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377(14):1345-56. Abstract